Serious technology. Big health claims. Know the difference before you buy.

Reviewed: July 2026
Company: Viome
Product reviewed: Gut Intelligence™ Test
Listed price at review: $279 USD for the standalone Gut Intelligence test. Promotional pricing and bundles may vary.
Sample type: Stool
Primary technology: Metatranscriptomics, meaning RNA-based analysis of microbial gene expression and activity
Main consumer outputs: Health scores, food recommendations, personalized recipes, optional prebiotic and probiotic products, and optional personalized supplements
Does the company sell products based on test results? Yes

guttitude’s take

Viome is one of the more technically ambitious companies in the consumer microbiome-testing market.

Its RNA-based stool metatranscriptomic platform is real science. Its publication record is more substantial than that of many companies selling gut-health dashboards. Viome is not simply counting a few bacteria and assigning you a cheerful or terrifying label.

But Viome is not only selling a measurement.

It is selling an interpretation engine: health scores, food lists, gut-health recommendations, custom biotics, supplements, and the broader suggestion that your stool sample can reveal what your body needs next.

That is a much bigger claim than “we can measure microbial RNA.”

The public evidence is strongest for Viome’s ability to generate detailed molecular readouts from stool. It is weaker for the consumer-facing leap from those readouts to proprietary health scores, food lists, and product recommendations that are meaningfully better than ordinary evidence-based nutrition guidance.

Bottom line: Viome may be interesting for a curious, informed consumer who understands it as an exploratory wellness product. It is not a diagnosis, a prognosis, a medical nutrition plan, or proof that you need a custom supplement subscription.

The guttitude Gut Test Scorecard

This is the same scorecard used for every gut-test company reviewed by guttitude.

Category

Viome rating

What this means

Test Method Clarity

✅ Strong

Viome clearly states that it uses stool metatranscriptomics to assess microbial gene expression and functional activity.

Scientific Transparency

🟡 Mixed / Limited

Viome has published methods papers, observational studies, and some outcome research. Important details behind consumer-facing algorithms and scores remain proprietary.

Reproducibility Evidence

🟡 Mixed / Limited

Viome has published within-platform stability data over time. Independent head-to-head replication and comparison with other laboratories remain limited.

Clinical Validation

🟡 Mixed / Limited

Viome has studies linking measured features with health-related traits, but many consumer scores are not independently validated as clinical measures.

Evidence for Recommendations

🟡 Mixed / Limited

Early trials are interesting, but public evidence does not yet prove that Viome-guided food and supplement plans outperform well-delivered standard care.

Claim Discipline

🟡 Mixed / Limited

Viome includes legal disclaimers, but its consumer presentation can make proprietary scores feel more medically definitive than the public evidence supports.

Commercial Pressure

High

Viome tests, interprets results, recommends next steps, and sells biotics and supplements linked to those results.

Consumer Usefulness

🟡 Mixed / Limited

It may provide useful prompts for an informed wellness consumer. It is not reliable enough for diagnosis, symptom investigation, or treatment decisions.

What the ratings mean

✅ Strong: The company clearly discloses relevant information and has meaningful public support for the claim being assessed.

🟡 Mixed / Limited: Some credible evidence or transparency exists, but important gaps remain.

🔴 Weak / Concerning: Public claims appear broader than the evidence, key methods are opaque, or consumer marketing risks being mistaken for clinical guidance.

⚪ Not publicly assessable: The company does not disclose enough information to judge the issue fairly.

What Viome Says It Does

Viome’s Gut Intelligence test uses stool RNA sequencing, also called metatranscriptomics.

Instead of only asking which microbial DNA is present in a stool sample, Viome says it measures which microbial genes are being expressed. In theory, this offers a more functional look at what the microbial community may be doing at the time of collection.

The company currently advertises:

• More than 25 health scores for its Gut Intelligence product
• More than 370 personalized food recommendations
• Guidance related to digestion, regularity, gas production, inflammation, gut-lining health, and metabolic function
• Personalized prebiotic and probiotic products
• Optional supplement formulas linked to test-derived recommendations

That is a polished and compelling consumer proposition.

You do not receive a plain list of bacterial names. You receive a story about your biology:

Here is your score.
Here is what may be driving it.
Here are foods to prioritize.
Here are foods to minimize.
Here are products designed around your results.

The problem is not that this kind of interpretation is impossible.

The problem is that the scientific burden rises sharply each time the company moves from measurement to meaning, from meaning to recommendation, and from recommendation to product.

What Viome Actually Measures

Viome’s core laboratory method is legitimate.

Metatranscriptomics measures RNA transcripts. In plain English, it attempts to capture which genes microbes are expressing in the sample. This is different from a DNA-only microbiome test, which can identify microbial genetic material without necessarily telling you whether those microbes are active at that moment.

Viome published a 2019 methods paper describing its Viomega platform, a high-throughput stool metatranscriptomic workflow designed to generate taxonomic and functional data at population scale.

That paper supports a straightforward claim:

Viome has built a real laboratory and computational platform capable of generating detailed molecular microbiome data from stool.

That matters. Many consumer microbiome products provide little explanation of their laboratory method, reference database, or analytical workflow.

Viome is more technically serious than that.

But this point needs to stay clear:

A company can measure something real and still overstate what that measurement can tell you.

A sophisticated assay does not automatically validate a gut-health score.

It does not automatically prove that one food is good or bad for you.

It does not automatically prove that a custom supplement is necessary.

And it does not automatically convert a stool sample into personalized medicine.

Viome’s Strongest Evidence: Broad Longitudinal Stability

Viome’s 2026 longitudinal metatranscriptomic paper is one of the more useful publications in its portfolio.

The study analyzed repeat stool samples from 6,157 Viome customers. Its core result was that broad stool metatranscriptomic taxonomic and functional profiles appeared relatively stable within individuals over an approximate six-month period.

That finding is useful.

It pushes back against the simplistic claim that every microbiome test is automatically meaningless because “your dinner last night changes everything.”

Broad microbial and functional patterns may be more stable over time than many people assume.

But the study needs to be read with restraint.

The larger customer cohort supports a claim about broad within-person stability across months. It does not establish that short-term meals never matter, that one stool sample can direct personalized nutrition, or that a stable measurement is automatically clinically actionable.

The paper’s more dramatic substudies were much smaller:

• Dense repeated sampling involved two people, both selected because they maintained unusually stable diets and lifestyles.
• The colonoscopy-resilience analysis involved five people.
• Participants received Viome’s personalized nutrition and supplement recommendations after baseline, but diet and supplement changes were not directly tracked.

That means the study cannot show that Viome’s recommendations caused people to move into a new microbiome state over six months.

It also cannot show that stool-profile stability translates into better clinical decisions, improved health outcomes, or preventive-medicine value.

The fair interpretation is narrower:

Viome’s 2026 study supports within-platform longitudinal stability of broad stool metatranscriptomic profiles. It does not yet prove a game changer for personalized nutrition or preventive medicine.

Important study. Useful dataset. Less LinkedIn, more restraint.

What Viome’s Publications Support

Viome’s public work supports several real accomplishments.

It has shown that it can:

• Run a technically sophisticated RNA-based stool microbiome workflow.
• Generate taxonomic and functional microbial readouts.
• Measure broad patterns that appear relatively stable within individuals across months.
• Identify associations between molecular features, diet-related variables, and health-related traits.
• Build machine-learning models that predict selected outcomes in selected datasets.
• Conduct at least some randomized outcome research rather than relying only on testimonials.

Those are meaningful strengths.

Viome is not operating with no science.

That said, the evidence becomes less settled as the company moves farther downstream from measurement.

What the public evidence does not yet establish

The public record does not yet show, at the level a consumer should demand, that Viome can reliably:

• Diagnose the cause of digestive symptoms.
• Determine whether a person has clinically meaningful inflammation.
• Identify a universal “healthy” microbiome.
• Tell a person which foods are objectively good or bad for them.
• Show that its food lists outperform well-delivered conventional nutrition guidance.
• Show that its custom supplements add benefit beyond standard diet and lifestyle advice.
• Demonstrate that improving one of its proprietary scores reduces disease risk or improves a meaningful clinical outcome.

That is not an accusation that Viome has no evidence.

It is a statement about the evidence bar.

A company that guides food choices, supplement use, digestive health, inflammation, metabolic function, and longevity needs more than plausible biology and attractive dashboards.

It needs reproducible outcome data.

The Personalized Nutrition Evidence Is Interesting, but Not Settled

Viome has published work suggesting that microbial activity contributes to differences in post-meal glycemic response.

That is a serious scientific question. People do not respond identically to the same food, and microbiome-related biology may be part of the reason why.

The more important question is whether Viome’s specific consumer recommendations improve outcomes.

Viome has reported a pilot randomized, placebo-controlled study in adults with prediabetes or diabetes. The interim analysis included 27 participants over roughly 90 days. The intervention group received personalized food recommendations plus Viome supplements and biotics. The comparison group received standard USDA dietary guidance and placebo supplements.

The preprint reported a greater HbA1c reduction in the Viome arm.

That is worth paying attention to.

A randomized design is much stronger than a customer testimonial or a before-and-after survey.

But it remains preliminary for several reasons:

• It is a preprint, not a peer-reviewed published paper.
• It is an interim analysis, not a completed definitive trial.
• It included only 27 participants.
• The intervention bundled personalized food guidance, supplements, and biotics together.
• It cannot isolate whether any benefit came from the test, the dietary advice, the supplements, the added structure, the extra attention, or a combination of all of those factors.
• Viome funded the study, and the authors were employees, contractors, or advisors of the company.

The responsible conclusion is:

Viome has early outcome data that justify larger, independent trials. It does not yet have enough public evidence to prove that its consumer recommendations should be treated as clinically validated precision nutrition.

Promising is not the same as proven.

The Score Problem

Viome’s consumer product is built around scores.

The company offers scores related to gut health, inflammatory activity, metabolic fitness, digestion, gut-lining health, gas production, protein fermentation, biological age, and other systems.

Scores are seductive because they feel objective.

They turn biological uncertainty into a number.

A number gives you something to optimize, compare, improve, fear, retest, and post about.

But a score becomes meaningful only when three questions have clear answers:

What exactly is the score measuring?

What real-world outcome does it predict?

Does improving the score improve anything that matters?

A green score is not automatically a health outcome.

A low inflammation score is not automatically evidence of lower inflammation in the medical sense.

A better gut-health score is not automatically evidence of better bowel function, better immune health, lower disease risk, or longer life.

Viome may have complex models behind its scores.

The question is not whether the model is complicated.

The question is whether a consumer can see enough independent validation to understand what the number truly means.

At present, much of that validation remains proprietary, company-controlled, difficult for an ordinary buyer to inspect, or not yet demonstrated through independent outcome studies.

That does not make the scores useless.

It means they should be treated as proprietary wellness metrics, not as medical findings.

The Commercial Conflict Is Real

Viome tests you, interprets your results, recommends actions, and then sells products designed around those results.

Its product lineup includes personalized prebiotic and probiotic blends. It also promotes custom supplement formulations containing ingredients selected from the customer’s test-derived recommendations.

That does not automatically mean the products are wrong.

But it creates an unavoidable conflict:

The company that defines the problem is also the company selling the solution.

A responsible buyer should ask:

• Would I receive the same recommendation from an independent registered dietitian or clinician?
• Is the recommendation understandable without Viome’s proprietary score?
• Has the company shown that its custom formula works better than a standard alternative?
• Am I buying a needed intervention, or am I buying the feeling of being precisely optimized?

The test may be a one-time purchase.

The subscription, retesting, biotics, and supplements can become the larger commercial relationship.

That is not unique to Viome. It is a structural issue across the personalized-wellness industry.

Still, it deserves to be visible.

What Viome Gets Right

Viome deserves credit for several things.

It is more scientifically ambitious than the average consumer microbiome company.

It has a genuine metatranscriptomic technology platform.

It has published technical and observational research rather than relying only on influencer marketing and generic “gut health” language.

It has built a large molecular dataset.

It has at least begun to conduct randomized outcome research.

And it states in its own materials that its product is not intended to diagnose, treat, cure, or prevent disease.

That matters.

The problem is not that Viome is a cartoon scam with a pretty dashboard.

The problem is that the emotional force of the consumer experience can exceed the caution contained in the fine print.

The dashboard feels more definitive than the evidence currently allows.

Who Might Find Viome Useful?

Viome may be reasonable for someone who:

• Enjoys quantified-self tools.
• Understands that the test is exploratory, not diagnostic.
• Wants broad lifestyle prompts rather than medical answers.
• Can afford it without treating the result as a high-stakes health purchase.
• Can avoid turning food recommendations into a restrictive eating project.
• Is comfortable declining the supplement upsell unless there is an independent reason to buy it.

Viome is a poor fit for someone who:

• Has concerning gastrointestinal symptoms that need clinical evaluation.
• Is trying to diagnose IBS, inflammatory bowel disease, celiac disease, infection, food allergy, or another medical condition.
• Is vulnerable to restrictive eating, food anxiety, or obsessive health tracking.
• Wants a clear explanation for fatigue, bloating, inflammation, mood symptoms, or weight changes.
• Is hoping a stool score will tell them precisely which supplement they need.
• Cannot comfortably afford recurring product subscriptions.

For persistent or concerning symptoms, start with a clinician who can take a complete history, evaluate the full context, and order validated tests when indicated.

A stool dashboard cannot do that.

guttitude’s Verdict

Viome is not fake science.

Its laboratory platform is technically sophisticated. Its publication record is meaningful. Its RNA-based approach is more serious than a simplistic “good bacteria versus bad bacteria” report.

Viome is also not yet precision medicine.

The evidence becomes thinner as you move from measurement to interpretation, from interpretation to recommendation, and from recommendation to claimed health outcomes.

That is the central issue.

Viome may be measuring something real. That is not the same as proving that every score, food list, and supplement recommendation is useful.

Buy Viome only if you understand what you are getting:

A sophisticated wellness product that may generate interesting data and useful prompts.

Not a diagnosis.
Not a prognosis.
Not a medical nutrition plan.
Not proof that your gut is broken.
Not proof that custom supplements are necessary.

Viome’s science deserves more respect than its marketing certainty.

Consumers deserve to know the difference.

How guttitude reviewed Viome

This review evaluates publicly available information as of July 2026, including product pages, stated claims, publications, study registrations, and disclosed conflicts of interest.

It does not independently test Viome’s laboratory performance, audit its proprietary algorithms, inspect individual customer reports, or evaluate the safety or effectiveness of any individual supplement formula.

The guttitude scorecard reflects public evidence, transparency, claim discipline, commercial incentives, and likely consumer usefulness.

It is not a medical recommendation, a laboratory certification, or a substitute for individualized clinical care.

Selected Sources

Hatch A, et al. A robust metatranscriptomic technology for population-scale studies of diet, gut microbiome, and human health. International Journal of Genomics. 2019. PMID: 31662956.

Toma R, et al. The human gut microbiome activity is resilient and stable: a longitudinal metatranscriptomic study.Microorganisms. 2026;14:835. doi:10.3390/microorganisms14040835.

Vuyisich M, et al. Data-driven personalized nutrition reduces HbA1c in a prediabetic and diabetic population: a pilot, randomized, placebo-controlled clinical trial. Preprint. 2024.

Viome. Gut Intelligence™ Test, Full Body Intelligence™ Test, health-score materials, product pages, and publications list. Accessed July 2026.